FTRP

Field Trip Health Ltd.

Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call

Appoints Stacey Hoisak as Senior Vice President, General Counsel, and Dr. Monique Moller as Vice President, Integrative HealthSchedules Fiscal Second Quarter 2023 Conference Call for Tuesday, November 29, 2022, at 8:30 AM ET TORONTO, Nov. 22, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or β€œField Trip”), a glo... Read More...

Field Trip Health & Wellness to Participate in the Cantor Fitzgerald Symposium on Mental Health Clinics on October 11th

TORONTO, Oct. 04, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or β€œField Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at Cantor Fitzgerald’s β€œSymposium on Mental Health Clinics,” taking place on Tuesday, October 11, 2022. Mujeeb Jafferi, Presi... Read More...

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Completed corporate reorganization on August 11, 2022 separating the drug development (β€œReunion Neuroscience Inc.” or β€œReunion”) and healthcare and wellness (β€œField Trip Health & Wellness” or β€œField Trip”) divisions into two separate public companies (the β€œSpinout Transaction”).Field Trip received listing approval from the TSX Venture... Read More...

Field Trip Health & Wellness Ltd. to Commence Trading on the TSX Venture Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 -- Field Trip Health & Wellness Ltd. (the "Company" of β€œField Trip”), a global leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares (the "Shares") will commence trading on the TSX Venture Exchange (β€œTSXV”) under the ticker symbol β€œFTHW” at the opening of ... Read More...

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Including Corporate Reorganization

Completed strategic review and announced intention to separate the Field Trip Discovery and Field Trip Health divisions into two independent public companies.Earned patient services revenues of $1.7 million in fiscal fourth quarter, an increase of 26.7% over the prior quarter and 228% year over year. Full year patient services revenue was... Read More...

Field Trip Health Ltd. Receives Final Court Approval for Reorganization of the Discovery and Wellness Businesses Into Two Publicly Traded Companies

- Closing of arrangement subject to regulatory approvals, including conditional listing approval by the TSX Venture Exchange.- Closing of the arrangement expected to occur in August.- Also announces closing of subscription receipt offering. TORONTO, June 29, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip" ... Read More...

Field Trip Health Ltd. to Present at the H.C. Wainwright 1st Annual Mental Healthcare Conference on June 27, 2022

TORONTO, June 23, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that Field Trip’s Co-founder and Executive Chairman, Ronan Levy, and Chief Scientific Officer, Dr. Nathan Bryson, will participate in a live fireside ... Read More...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET

TORONTO, June 22, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year ended March 31, 2022, after market close on Wednesday, June 29,... Read More...

Field Trip Health Ltd. Announces Increased Participation in Arrangement Financing and Postponement of Shareholder Meeting Date

TORONTO, June 14, 2022 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the "Company" or "Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of ... Read More...

Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104

TORONTO, April 05, 2022 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced that the U.S. Patent and Trademark Office (β€œUSPTO”) has granted the Company a patent for claims related to FT-104 (informally known as β€œIsoprocin Glutarate”),... Read More...

Field Trip Health Ltd. Reports Second Fiscal Quarter 2022 Financial Results and Provides Business Update

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications.Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk profile compared to classic psychedelics (the β€œFT-200 Group... Read More...

Field Trip Health Ltd. Continues Expansion WithΒ Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and Fredericton

TORONTO, Oct. 19, 2021 -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the opening of their Seattle clinic, their sixth in the United States, along with the recent opening of a location in Fredericton, NB, and the imminent opening... Read More...

Field Trip Health Announces Voting Results From the Annual General and Special Meeting of Shareholders

TORONTO, Sept. 24, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; Nasdaq: FTRP) ("Field Trip"), today announced the voting results from its Annual General and Special Meeting of Shareholders held onΒ Friday, September 24, 2021.Β A total of 59.09% of the issued and outstanding common shares of the Corporation were represented either in ... Read More...

Field Trip Health Ltd. to Pursue Treatment Resistant Depression and Postpartum Depression as Indications for FT-104

TORONTO, Sept. 09, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; NASDAQ: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today the lead indications for FT-104, its novel psychedelic compound in development, will be Treatment Resistant Depression (TRD) and Postpartum Depressio... Read More...

Field Trip Health Ltd. Announces Launch Of β€œKap Co-Operative” Program, Enabling Independent Psychedelic Therapists To Practice At Its Field Trip Health Centers; Also Launches Training Programs To Educate A New Generation Of Psychedelic Clinicians

The KAP Co-op program gives eligible therapists the ability to provide ketamine-assisted psychotherapy (KAP) to their patients at Field Trip Health Centers utilizing Field Trip’s medical teams for screening, prescribing and administration of ketamine.Training programs will provide both didactic and experiential training to therapists and ... Read More...

Field Trip Health Ltd. Schedules First Fiscal Quarter 2022 Financial Results Conference Call for Tuesday, August 17, 2021 at 8:30 am ET

TORONTO, Aug. 10, 2021 -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its first fiscal quarter ended June 30, 2021, after market close on Monday, August 16, 2021. The Compan... Read More...

Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

TORONTO, July 27, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip" or the β€œCompany”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC (β€œNASDAQ”) to list its common shares on the NASDAQ Global Select... Read More...

Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results

Field Trip completes FY2021 as the largest vertically integrated psychedelics company positioned to be a leader in the emerging industryContinues to leverage its early mover opportunity by investing in its drug development strategy and the build out of a globally recognized brand of psychedelic-assisted therapy centersClosed FY2021 with $... Read More...

Field Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call for Friday, June 25, 2021 At 8:00 am ET

TORONTO, June 17, 2021 -- Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that it plans to release financial results for its fiscal fourth quarter and full year 2021 ended March 31, 2021, after market close on Thursday, June... Read More...